Physician profile
Nitin Tandan
NPI 1346777026
$3,642.82
in general payments reported to CMS, 2019-2025
24 companies · $30.22 in 2025
The $30.22 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.71 · 2021: $528 · 2022: $1,299 · 2023: $1,034 · 2024: $732 · 2025: $30.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $954.79 | 2021-2024 | Merlin@Home, Fortify Assura, Ensite Precision |
| Novartis Pharmaceuticals Corporation | $530.12 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $403.85 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $237.60 | 2019-2024 | Xarelto |
| Medtronic, INC. | $165.57 | 2022-2023 | Azure Xt Dr Mri Surescan, Micra |
| Amgen INC. | $154.81 | 2022-2024 | Repatha |
| Pfizer INC. | $154.20 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $153.27 | 2021-2024 | Farxiga, Andexxa |
| Actelion Pharmaceuticals US, INC. | $122.46 | 2021-2024 | Uptravi |
| Boston Scientific Corporation | $114.97 | 2021-2024 | Emblem Mri S-Icd |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Livanova USA, INC. | $94.49 | 2022-2023 | Tandemlife |
| Biosense Webster, INC. | $85.24 | 2022-2023 | Qdot Micro Catheter, Soundstar, Na |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.09 | 2022-2023 | Jardiance |
| Abiomed | $55.06 | 2023 | Impella |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $48.10 | 2023-2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $44.02 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.71 | 2022-2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $28.07 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.25 | 2024 | Onpattro |
| Esperion Therapeutics, INC. | $19.02 | 2021 | |
| Cook Medical LLC | $18.48 | 2023 | Evolution |
| Novo Nordisk INC | $18.25 | 2023 | Ozempic |
| Biotronik INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Tandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.